Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Multiple Sclerosis
- Sponsor
- Kessler Foundation
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Neuropsychological measures of thinking
- Status
- Recruiting
- Last Updated
- 5 months ago
Overview
Brief Summary
The purpose of this research study is to evaluate the usefulness of a wearable robotic exoskeleton device (Ekso-GT), to improve learning and memory, and gait therapy in persons with walking disability due to Multiple Sclerosis. The study will evaluate the mobility, learning and memory, and walking abilities of individuals with multiple sclerosis who went through the traditional as compared to others who used the robotic exoskeleton as part of their therapy.
Investigators
Ghaith J. Androwis, Ph.D.
Assistant Director
Kessler Foundation
Eligibility Criteria
Inclusion Criteria
- •Be diagnosed with multiple sclerosis.
- •Be determined by the study staff to have moderate to severe difficulty walking but still be able to walk while using the robotic exoskeleton.
- •Have some difficulty thinking and problem solving as determined by my performance on a special test that I will take during the screening visit.
- •Be between the ages of 18 and
- •Be free from flair ups of my MS Symptoms for at least one month prior to testing.
- •Discuss with study staff how to maintain a constant level of my spasticity medication (for example baclofen) throughout the study.
- •Be able to walk (with the use of one or more assistive device if needed).
- •Have English as my primary language.
- •Be able to physically fit into the exoskeleton device: height between 60 and 76", weight under 220 lbs.
- •Be able to tolerate upright standing for 30 minutes with assistance if needed.
Exclusion Criteria
- •Have a history of head injury, stroke, seizures, or any other significant neurological history other than MS.
- •Have a high degree of difficulty in thinking and problem solving that prevents me from participating in the study as determined by my performance on a special test taken during the screening visit.
- •Be currently taking steroids, benzodiazepines, antipsychotics, and/or neuroleptics as determined by study staff review of my medications.
- •Be pregnant.
- •Be completely reliant on a wheelchair.
- •Have joint contracture or spasticity of any limb that limits normal range of motion during walking with assistive devices as determined by study staff.
- •Have skin issues that would prevent wearing the RE.
- •Have pressure sore stage 2 or higher located in an area that would negatively affect weight bearing, harness fit, or therapist assistance.
- •Have orthopedic issues or history that will interfere with walking or limit the range of motion of the lower limbs (e.g., knee replacement, inflammation)
- •Have been hospitalized for heart attack, heart surgery or acute heart failure within 3 months of enrollment in study.
Outcomes
Primary Outcomes
Neuropsychological measures of thinking
Time Frame: approximately 12 weeks
Processing speed and cognition outcomes, including: The Symbol Digit Modalities Test (SDMT) represents the primary CPS outcome in the current proposal. This test involves the conversion of a set of simple geometric designs into an oral response. It has been demonstrated to be sensitive to the presence of brain damage in numerous studies. The SDMT requires the examinee to substitute a number for a randomized presentation of a geometric figure. The appropriate number is shown in a key containing the Arabic numbers 1 through 9, each paired with a different geometric figure. The total number of correct responses in 90 seconds is the primary outcome of the SDMT.
Brain scans
Time Frame: approximately 12 weeks
Participants will undergo neuroimaging scans of the brain to acquire structural imaging of the brain using Magnetic resonance imaging (MRI). The MRI instrument that will be used is an FDA-approved Siemens Skyra 3T clinical imager housed in the Rocco Ortenzio Neuroimaging Center at Kessler Foundation.
Distance walked in a specific time duration
Time Frame: approximately 12 weeks
The distance walked (meters) in 6 minutes is measured. This is following the 6-minute walk test (6MWT) procedure to measure walking endurance. The 6MWT is is a valid and reliable test of endurance walking performance in persons with MS. Participants are instructed to walk as fast and as far as possible for 6 minutes within a single corridor and performing 180° turns.